Expert Ratings for Harpoon Therapeutics
Portfolio Pulse from Benzinga Insights
Harpoon Therapeutics (NASDAQ:HARP) received three bullish analyst ratings in the last quarter with an average price target of $19.33, representing significant upside from the current price of $8.55. This target is a 42.3% decrease from the previous target of $33.50. Analysts base their ratings on various data including company performance and insider conversations.
December 13, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harpoon Therapeutics has received three bullish analyst ratings with no bearish or neutral positions. The average price target suggests a substantial upside from the current trading price, but it's a significant decrease from the previous target.
The unanimous bullish sentiment from analysts and the high price target compared to the current price suggest a positive short-term impact on HARP's stock price. However, the decrease in the target from the previous average indicates some caution, which might temper the positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100